Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Overview of attention for article published in Trials, August 2021

Altmetric Badge

Mentioned by

news: 1 news outlet
policy: 1 policy source

twitter: 11 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 107 Mendeley

Summary News Policy documents X Dimensions citations

So far, Dimensions has found 38 publications that cite this research output.

38

The most recent citing publications are shown below. View all 38 publications that cite this research output on Dimensions.

A comparative study of electropolymerization and photopolymerization for the determination of molnupiravir and their application in an electrochemical sensor via computationally designed molecularly imprinted polymers

Article in Microchimica Acta (April 2024)

Favipiravir vs. Deferiprone: Tautomeric, photophysical, in vitro biological studies, and binding interactions with SARS-Cov-2-MPro/ACE2

Article in Current Research in Biotechnology (January 2024)

Preparation and Characterization of Fe-Gallic acid MOF for determination of antiviral Molnupiravir as inhibitor for RNA Corona virus replication

Article in Microchemical Journal (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.